Staying One Step Ahead of Resistance
How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance
Award-winning startup at TWINCORE
Frank Pessler's spin-off honoured as "Emerging Startup" at BioVaria 2025
Prof Frank Pessler, Head of the TWINCORE research group Biomarkers for Infectious Diseases, received the Emerging Startup award for his spin-off Citrapeutics at the BioVaria 2025 conference in Munich.
Citrapeutics aims to develop active substances that can restore immune function in infections or cancer. Pessler and his team described the antioxidant and anti-inflammatory effect of citraconic acid in the journal Nature Metabolism in 2022. They subsequently founded Citrapeutics to further develop these and other substances into active pharmaceutical ingredients.
In the photo: Frank Pessler (left) and his team member Fakhar Waqas with the award. ©TWINCORE/T. Damm
Other posts
Antibodies produced following the Ebola vaccination neutralise the current Bundibugyo virus variant
A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.
Booster vaccination strengthens existing defences
Memory B cells play a key role in adapting to new coronavirus variants